Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update
– Completed $25 Million Strategic Financing; Extending Cash Runway into 2023
– Accelerated Development of AL102 Desmoid Tumor Program into Phase 2/3 Pivotal Trial
– On Track to Report Multiple Milestones in 2021 Across Clinical-Stage Pipeline
REHOVOT, Israel and WILMINGTON, Del., March 25, 2021 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc.